TK2 and Mitochondrial myopathy: Domínguez-González et al. performed a clinical trial based on the use of pyrimidine deoxynucleoside and deoxynucleotides as novel pharmacological therapies in 16 patients with mitochondrial myopathy due to TK2 deficiency.